HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CXCR2 inhibition enhances sulindac-mediated suppression of colon cancer development.

Abstract
Small chemical compound sulindac has been approved as a preventive approach against colon cancer for its effectiveness in treatment of precancerous adenoma. Due to its severe toxicities in the cardiovascular, gastrointestinal and renal systems, however, a combination of low-dose sulindac with other chemopreventive agents has been sought after as an alternative therapeutic strategy that could increase its effectiveness, while minimizing its adverse effects. To identify the promising alternative approach, we investigated the therapeutic potential of targeting the interleukin (IL)-8/CXCR2 pathway in colon cancer treatment using both loss-of-function (CXCR2 knockout) and gain-of-function (IL-8 overexpression) mouse models, as the IL-8/CXCR2 pathway has been shown to be activated in intestinal tumors of both human and experimental animals. We found that deletion of CXCR2 gene and ectopic expression of IL-8 suppresses and enhances, respectively, intestinal tumor development caused by a mutation in the APC gene. Moreover, a single copy deletion of CXCR2 gene resulted in abrogation of COX-2 and Gro-α upregulation in intestinal tumors caused by the APC mutation. Moreover, a single copy (heterozygote) deletion of CXCR2 gene was sufficient to synergize with a low-dose sulindac treatment in suppressing APCmin-induced intestinal polyposis. Together, our study provides a therapeutic justification of combined inhibition of CXCR2 and sulindac treatment in colon cancer prevention.
AuthorsYong Suk Lee, Dongwon Choi, Nam Yoon Kim, Sara Yang, Eunson Jung, Mingu Hong, Dongyun Yang, Heinz-Josef Lenz, Young-Kwon Hong
JournalInternational journal of cancer (Int J Cancer) Vol. 135 Issue 1 Pg. 232-7 (Jul 01 2014) ISSN: 1097-0215 [Electronic] United States
PMID24338666 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2013 UICC.
Chemical References
  • APC protein, human
  • Adenomatous Polyposis Coli Protein
  • Receptors, Interleukin-8B
  • Sulindac
  • Cyclooxygenase 2
  • PTGS2 protein, human
Topics
  • Adenomatous Polyposis Coli Protein (biosynthesis)
  • Animals
  • Carcinogenesis (drug effects)
  • Colonic Neoplasms (drug therapy, genetics, pathology, prevention & control)
  • Cyclooxygenase 2 (biosynthesis)
  • Gene Expression Regulation, Neoplastic (drug effects)
  • Humans
  • Mice
  • Mice, Knockout
  • Neoplasms, Experimental (genetics, prevention & control)
  • Receptors, Interleukin-8B (antagonists & inhibitors, genetics)
  • Sulindac (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: